Published in Cancer Weekly, August 16th, 2005
Valeant is evaluating the safety and efficacy of pradefovir for the treatment of compensated chronic hepatitis B. Pradefovir is a prodrug of adefovir that was that was discovered by Metabasis and uses Metabasis' HepDirect technology which allows for higher concentrations of the drug in the liver, the primary site of hepatitis B (HBV) replication. Metabasis has licensed pradefovir to Valeant.
The phase 2 study conducted by Valeant is an open-label, randomized,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.